#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Primitive neuroectodermal tumour Retinoblastoma Autoimmune haemolytic anaemia Oesophageal squamous cell carcinoma stage II Prophylaxis against transplant rejection Factor VIII deficiency Spinal cord injury Non-Hodgkin's lymphoma unspecified histology aggressive recurrent Immune thrombocytopenia Thymic carcinoma Ischaemic stroke Skin cancer Mucopolysaccharidosis II Non-renal cell carcinoma of kidney Mantle cell lymphoma recurrent More trials…

    Learn about Rare Diseases

    Synovial sarcoma – Life with Disease Cerebral arteriovenous malformation haemorrhagic – Trials in Disease Glomerulonephritis membranous – Treatment Hairy cell leukaemia – Trials in Disease Nephrotic syndrome – Diagnostics Mantle cell lymphoma refractory – Diagnostics Stevens-Johnson syndrome Basal cell naevus syndrome Haemophilia A without inhibitors Medulloblastoma recurrent – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Nortriptyline Cannabis Sativa Flower Vorasidenib Cx-044933 Cln-081 Ivospemin Magnesium Hydroxide Ramipril Protrans Vildagliptin Ralinepag Sqy51 Transpocart19 Mepolizumab Ofatumumab Cft1946 Aon-D21 Ilofotase Alfa Mifamurtide Siremadlin More therapies…

    Learn about Your Condition

    Metabolic disorder Metastases to rectum Catatonia Ovarian epithelial cancer Pharyngeal cancer stage II Cushing's syndrome Thymic carcinoma Mantle cell lymphoma stage IV Necrotising myositis Sickle cell anaemia Stress cardiomyopathy Ocular melanoma Premature baby Orthostatic hypotension Myotonic dystrophy More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Landeskrankenanstalten-Betriebsgesellschaft Kabeg

Landeskrankenanstalten-Betriebsgesellschaft Kabeg

Feschnigstrasse 11, Klagenfurt,09.Bez.:Annabichl, Klagenfurt am Wörthersee, 9020, Austria

Want to learn more about this study or check if you can participate? Contact us.

  • A Study of Depemokimab Compared to Placebo in Adults with Chronic Obstructive Pulmonary Disease and Type 2 Inflammation

    Recruiting

    3 1 1
    Investigated Drugs:
    • Depemokimab
    • Salbutamol Sulfate
    Austria Bulgaria Czechia Germany Greece Italy +2

  • Triple vs dual therapy with rosuvastatin, ezetimibe and bempedoic acid in patients with atherosclerotic heart disease and high cholesterol undergoing revascularisation

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Bempedoic Acid
    • Ezetimibe
    • Rosuvastatin
    Austria Germany

  • Study of JNJ-78934804 (guselkumab and golimumab) versus guselkumab in adults with moderately to severely active Crohn’s disease

    Recruiting

    3 1 1
    Investigated Drugs:
    • Golimumab
    • Guselkumab
    Austria Belgium Czechia France Germany Greece +9

  • Efficacy and Safety of JNJ-78934804 (guselkumab and golimumab) in Adults with Moderately to Severely Active Ulcerative Colitis

    Recruiting

    3 1 1
    Investigated Drugs:
    • Golimumab
    • Guselkumab
    Austria Belgium Bulgaria Czechia Denmark France +11

  • High-Dose Colecalciferol for 28-Day Mortality in Critically Ill Adults with Severe Vitamin D Deficiency

    Recruiting

    3 1 1
    Investigated Diseases:
    • Vitamin D deficiency
    • Critical illness
    Investigated Drugs:
    • Colecalciferol
    Austria Germany

  • Comparing Sotorasib and Pembrolizumab with chemotherapy for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Hydroxocobalamin
    • Sotorasib
    • Betamethasone Sodium Phosphate Ph. Eur
    Austria Belgium Bulgaria Czechia Denmark France +11

  • Study of Revumenib and Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia with NPM1 Gene Mutation

    Recruiting

    3 1 1
    Investigated Diseases:
    • Acute myeloid leukaemia
    Investigated Drugs:
    • Revumenib
    • Idarubicin Hydrochloride
    • Daunorubicin Hydrochloride
    Austria Belgium Czechia France Germany Greece +7

  • A Study of MK-1084 and Drug Combination Versus Pembrolizumab and Chemotherapy for Adults with Advanced Lung Cancer with KRAS G12C Mutation

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Carboplatin
    • Cisplatin
    • Mk-1084
    Austria Belgium France Germany Greece Hungary +5

  • Study of incobotulinumtoxinA injections for prevention of chronic migraine in adult patients

    Recruiting

    3 1 1
    Investigated Diseases:
    • Migraine
    Investigated Drugs:
    • Clostridium Botulinum Neurotoxin Type A (150Kd), Free Of Complexing Proteins
    Austria Czechia Denmark France Germany Italy +3

  • Study of maridebart cafraglutide to reduce cardiovascular problems in overweight or obese patients with atherosclerotic cardiovascular disease

    Recruiting

    3 1
    Investigated Diseases:
    • Arteriosclerosis
    Investigated Drugs:
    • Maridebart Cafraglutide
    Austria Belgium Bulgaria Czechia Denmark Finland +12
1 2 3 … 6
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!